Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Accounts Payables: 2017-2025

Historic Accounts Payables for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $33.7 million.

  • Crinetics Pharmaceuticals' Accounts Payables rose 84.28% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.7 million, marking a year-over-year increase of 84.28%. This contributed to the annual value of $21.5 million for FY2024, which is 7.45% down from last year.
  • Crinetics Pharmaceuticals' Accounts Payables amounted to $33.7 million in Q3 2025, which was down 11.58% from $38.1 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Accounts Payables registered a high of $38.1 million during Q2 2025, and its lowest value of $6.2 million during Q3 2021.
  • For the 3-year period, Crinetics Pharmaceuticals' Accounts Payables averaged around $25.3 million, with its median value being $23.2 million (2023).
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Accounts Payables dropped by 25.11% in 2021, and later surged by 139.78% in 2022.
  • Over the past 5 years, Crinetics Pharmaceuticals' Accounts Payables (Quarterly) stood at $8.5 million in 2021, then soared by 81.28% to $15.4 million in 2022, then spiked by 51.10% to $23.2 million in 2023, then fell by 7.45% to $21.5 million in 2024, then spiked by 84.28% to $33.7 million in 2025.
  • Its Accounts Payables stands at $33.7 million for Q3 2025, versus $38.1 million for Q2 2025 and $31.6 million for Q1 2025.